Women and cardiovascular disease - Prevention of heart disease

International Journal of Angiology

Volumn 14, Issue 4, 2006, Pages 218-224

  Whayne Jr , Thomas F ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; CHOLESTEROL; EZETIMIBE; GEMFIBROZIL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PIOGLITAZONE; POLICOSANOL;

ARTICLE; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; DIABETES MELLITUS; FEMALE; GENDER; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS;

EID: 33747410920     PISSN: 10611711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00547-005-2031-0     Document Type: Article

References (53)

1. Arbustini E, DelBello B, Morbini P (1999) Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart 82:269-272.
2. Backman J, Kyrklund C, Neuvonen M, Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685-691.
3. Bays H, Moore PB, Drehobl MA, et al. for Ezetimibe Study Group (2001) Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 23:1209-1230.
4. Berglund L, Ramakrishnan R (2004) Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vase Biol 24:2219-2226.
5. Berthold H, Parhofer KG, Ritter MM, Addo M, Wasmuth JC, Schliefer K, Spengler U, Rockstroh JK (1999) Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med 246:567-575.
6. Cannon C, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes (PROVE-IT). N Engl J Med 350:1495-1504.
7. Canto J, Shlipak MG, Rogers WJ, Malmgren JA, Frederick PD, Lambrew CT, Ornato JP, Barron HV, Kiefe CI (2000) Prevalence, clinical characteristics and mortality among patients with myocardial infarction presenting without chest pain. JAMA 283:3223-3229.
8. Castano G, Menendez R, Mas R, Amor A, Fernandez JL, Gonzalez RL, Lezcay M, Alvarez E (2002) Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. Int J Clin Pharmacol Res 22:89-99.
9. Chai A, Abrams J (2001) Homocysteine: a new cardiac risk factor. Cliin Cardiol 24:80-84.
10. Chiquette E, Ramirez G, Defronzo R (2004) A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 164:2097-2104.
11. Clearfield M (2004) Coronary heart disease risk reduction in postmenopausal women: the role of statin therapy and hormone replacement therapy. Prev Cardiol 7:131-136.
12. Crane F (2001) Biochemical functions of coenzyme Q10. J Am Coll Nutri 20:591-598.
13. Davidson M, Ose L, Frohlich J, Scott RS, Dujovne CA, Escobar ID, Bertolanii MC, Cihon F, Maccubbin DL, Mercuri M (2003) Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-l are consistent across hypercholesterolemic patient subgroups. Clin Cardiol 26:509-514.
14. Davignon J (2004) The cardioprotective effects of statins. Curr Atheroscler Rep 6:27-35.
15. Downs J, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622.
16. Glaser R, Herrman HC, Murphy SA, Demopoulos LA, DiBattiste PM, Cannon CP, Braunwald E (2002) Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA 288:3124-3129.
17. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62:707-714.
18. Gotto A (1998) The new cholesterol education imperative and some comments on niacin. Am J Cardiol 81:492-494.
19. Gouni-Berthold I, Berthold HK (2002) Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 143:356-365.
20. Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jimenez F, Hardin PA, Kondoy CS, Tan MH (2003) A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 25:1074-1095.
21. Hochman J, Tamis JE, Thompson TD, Weaver WD, White HD, Van de Werf F, Aylward P, Topol EJ, Califf RM (1999) Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes lib Investigators. N Engl J Med 341:226-232.
22. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the Heart, Estrogen/progestin Replacement Study (HERS) Research Group (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613.
23. Istvan ES, Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292:1160-1164.
24. Jha A, Varosy PD, Kanaya AM, Hunninghake DB, Hlatky MA, Waters DD, Furberg CD, Shlipak MG (2003) Differences in medical care and disease outcomes among black and white women with heart disease. Circulation 108:1089-1094.
25. Jones P, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, for the STELLAR Study Group (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 92:152-160.
26. Kalin M, Zumoff B(1990) Sex hormones and coronary disease: a review of the clinical studies. Steroids 55:330-352.
27. Kent S, Flaherty PJ, Coyle LC, Markwood TT, Taylor AJ (2003) Effect of atorvastatin and pravastatin on serum C-reactive protein. Am Heart J 145:E8.
28. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357.
29. Lowe D, Rumley A, McMahon AD, Ford I, O'Reilly DSJ, Packard CJ, for the West of Scotland Coronary Prevention Study Group (2004) Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 24:1529-1534.
30. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, et al. (1988) Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260:641-651.
31. Maron D (2004) Flavonoids for reduction of atherosclerotic risk. Curr Atheroscler Rep 6:73-78.
32. Marrugat J, Sala J, Masia R, Pavesi M, Sanz G, Valle V, Molina L, Seres L, Elosua R, for the RESCATE Investigators (1998) Mortality differences between men and women following first myocardial infarction. JAMA 280:1405-1409.
33. Mesotten D, Swinnen JV, Vanderhoydonc F, Wouters PJ, Van den Berghe G (2004) Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocrinol Metab 89:219-226.
34. Ninomiya J, LItalien G, Criqui MH, Whyte JL, Gamst A, Chen RS (2004) Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 109:42-46.
35. Nissen S, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial (REVERSAL). JAMA 291:1071-1080.
36. Ornish D, Scherwitz LM, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide R, Hogeboom C, Brand RJ (1999) Intensive lifestyle changes for reversal of coronary heart disease. JAMA 281:2001-2007.
37. Pearson T, Laurora I, Chu H, Kafonek S (2000) The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160:459-467.
38. Post Coronary Artery Bypass Graft Trial Investigators (1997) The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 337:153-162.
39. Ridker P (2004) Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice. Am Heart Hosp J 2(Suppl) 1:4-9.
40. Sacks F, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335:1001-1009.
41. Sager P, Melani L, Lipka L, Strony J, Yang B, Suresh R, Veltri E, Ezetimibe Study Group (2003) Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 92:1414-1418.
42. Scandinavian Simvastatin Survival Group (1994) Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389.
43. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JG, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307.
44. Stamler J, Wentworth D, Neaton JD (1986) Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256:2823-2828.
45. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC (2005) Effect of different antilipidemic agents and diets on mortality. Arch Intern Med 165:725-730.
46. Szmitko P, Verma S (2005) Antiatherogenic potential of red wine: clinician update. Am J Physiol Heart Circ Physiol 288:H2023-H2030.
47. Tardif J (2005) Antioxidants and atherosclerosis: emerging drug therapies. Curr Atheroscler Rep 7:71-77.
48. Vaccarino V, Parsons L, Every NR, Barren HV, Krumholz HM (1999) Sex-based differences in early mortality after myocardial infarction. N Engl J Med 341:217-225.
49. Vaccarino V, Krumholz HM, Yarzebski J, Gore JM, Goldberg RJ (2001) Sex differences in 2-year mortality after hospital discharge for myocardial infarction. Ann Intern Med 134:173-181.
50. Wallerath T, Poleo D, Li H, Forstermann U (2003) Red wine increases the expression of human endothelial nitric oxide synthase: a mechanism that may contribute to its beneficial cardiovascular effects. J Am Coll Cardiol 41:471-478.
51. Whayne T, Zielke JC, Dickson LG, Winters JL (2002) State of the art treatment of the most difficult low density lipoprotein (LDL) cholesterol problems:LDLapheresis. J Ky Med Assoc 100:535-538.
52. Wright C, Zielke J, Whayne TF (2005) Policosanol, an aliphatic alcohol sugarcane derivative: use in patients intolerant of or inadequately responsive to statin therapy. Int J Angiol 13:173-175.
53. Zeff R, Kongtahworn C, Iannone LA, Gordon DF, Brown TM, Phillips SJ, Skinner JR, Spector M (1988) Internal mammary artery versus saphenous vein graft to the left anterior descending coronary artery: prospective randomized study with 10-year follow-up. Ann Thorc Surg 45:533-536.